Palvella Therapeutics to Report Phase 3 SELVA Trial Results for QTORIN™ Gel

Palvella Therapeutics has announced a conference call to discuss the topline results from its Phase 3 SELVA clinical trial. The study evaluates the efficacy of QTORIN™ 3.9% Rapamycin Anhydrous Gel in treating Microcystic Lymphatic Malformations. Scheduled for February 24, 2026, at 8:00 am ET, the call will provide critical clinical data that determines the regulatory path for the company's lead product. Investors are closely monitoring the outcome, as Phase 3 results are a pivotal milestone for the commercial viability of biotechnology firms. Positive data could significantly enhance the company's market valuation and pave the way for regulatory submissions. Conversely, any failure to meet primary endpoints could lead to substantial volatility in the company's stock price.